Blood test may lead to targeted therapy for prostate cancer

Conclusion Genetic testing is becoming more common in cancer treatment as a way of tailoring treatment to the individual cancer. It's already used in breast cancer, for example. This test could help identify which men that have not responded to hormone treatment are most likely to benefit from two of the newer prostate cancer drugs. It is good news, because men could then be spared treatment that is unlikely to help them, and directed towards more suitable treatment options. Also, both of these newer drugs are very expensive, so a suitable test could save the NHS a great deal of money. Meanwhile, those men who are likely to benefit will take the drug knowing it's likely to help. However, we're some way off being able to use the test in practice. This research shows that, among a group of 265 men, those with multiple copies of the androgen receptor gene did worse after treatment than those without. That doesn't prove that selecting patients for treatment based on AR gene status will improve outcomes. We need to see studies that select patients for treatment based on their test results, and follow them up to see how they do, to be sure the test is truly helpful. Links To The Headlines Prostate cancer: Blood test could help target treatment. BBC News, May 4 2017 Blood test could help prostate cancer treatment. ITV News, May 4 2017 £50 blood test boosts chances of surviving prostate cancer. The Times, May 4 2017 (subscription required) Links To Science Conteduc...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Medication Source Type: news

Related Links:

Authors: Wu Z, Huang W, Chen Y, Chen B, Liu R, Bai P, Xing J Abstract LINC01638 lncRNA is known as an oncogenic lncRNA in triple negative breast cancer. However, the role of LINC01638 lncRNA in other diseases is unknown. In the present study we observed that plasma levels of LINC01638 lncRNA and Notch1 were upregulated in prostate carcinoma patients comparing with healthy controls. LINC01638 lncRNA and Notch1 were positively correlated in prostate carcinoma patients but not in healthy controls. Upregulation of LINC01638 lncRNA distinguished prostate carcinoma patients from healthy controls. LINC01638 lncRNA overexp...
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Publication date: Available online 18 May 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Zoran CuligAbstractEpithelial to mesencyhmal transition (EMT) has a central role in tumor metastasis and progression. EMT is regulated by several growth factors and pro-inflammatory cytokines. The most important role in this regulation could be attributed to transforming growth factor-β (TGF-β). In breast cancer, TGF-β effect on EMT could be potentiated by Fos-related antigen, oncogene HER2, epidermal growth factor, or mitogen-activated protein kinase kinase 5 – extracellular-re...
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
Individuals who smoke are much less likely than nonsmokers to participate in...Read more on AuntMinnie.comRelated Reading: Cancer screening rates dip with appointments later in day Prostate cancer incidence, mortality decline worldwide Earlier colon screening saves lives -- but at what cost? How has the ACA affected breast cancer screening? Cancer death rates decline, but economic gap remains
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
CONCLUSION: Although a personal history of these malignancies does represent a statistically significant risk factor for acute VTE after anatomic TSA, the overall VTE rate remains modest and acceptable. The rates of other surgical and medical complications are not significantly increased in patients with a history of these cancers after TSA compared with control subjects. PMID: 31082867 [PubMed - as supplied by publisher]
Source: The Journal of the American Academy of Orthopaedic Surgeons - Category: Orthopaedics Tags: J Am Acad Orthop Surg Source Type: research
Publication date: Available online 14 May 2019Source: Molecular and Cellular EndocrinologyAuthor(s): Yue Zhang, Sajina Gc, Sweta B. Patel, Ying Liu, Andrew J. Paterson, John C. Kappes, Jing Jiang, Stuart J. FrankAbstractHuman growth hormone (GH) binds and activates GH receptor (GHR) and prolactin (PRL) receptor (PRLR). LNCaP human prostate cancer cells express only GHR. A soluble fragment of IGF-1 receptor (IGF-1R) extracellular domain (sol IGF-1R) interacts with GHR and blocks GH signaling. We now explore sol IGF-1R's specificity for inhibiting GH signaling via GHR vs. PRLR and test GHR and PRLR extracellular domain inhib...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
Publication date: Available online 10 May 2019Source: Materials Science and Engineering: CAuthor(s): M.I. Abou-Dobara, N.F. Omar, M.A. Diab, A.Z. El-Sonbati, Sh.M. Morgan, O.L. Salem, A.M. EldesokyAbstractThe Cu2+, Co2+, Ni2+ and UO22+ polymer complexes of 5-(2,3-dimethyl−1-phenylpyrazol-5-one azo)-8-hydroxyquinoline (HL) ligand were prepared and characterized. Elemental analyses, IR spectra, X-ray diffraction analysis and thermal analysis studies have been used to confirm the structure of the prepared polymer complexes. The chemical structure of metal chelates commensurate that the ligand acts as a neutral bis(biden...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
AbstractPurpose of ReviewThe rise of routine integration of genetic testing into oncological pathways, through initiatives such as mainstream testing, is making it increasingly important for oncologists to understand more about the wider implications of inherited mutations in cancer susceptibility genes. This is vital to facilitate accurate information-giving by oncologists, taking informed consent for testing, and to ensure they are referring patients appropriately for risk reduction strategies such as screening. In this review, the most relevant information for oncologists discussing and consenting patients will be discu...
Source: Current Genetic Medicine Reports - Category: Genetics & Stem Cells Source Type: research
AbstractThis systematic review evaluated the effectiveness of strategies to identify and manage patients with familial risk of breast, ovarian, colorectal and prostate cancer in primary care to improve clinical outcomes. MEDLINE, EMBASE, CINAHL and Cochrane library were searched from January 1980 to October 2017. We included randomised controlled trials (RCT) and non-randomised studies of interventions (NRSI). Primary outcomes were cancer incidence, cancer-related clinical outcomes or the identification of cancer predisposition; secondary outcomes were the appropriateness of referral, uptake of preventive strategies and co...
Source: Journal of Community Genetics - Category: Genetics & Stem Cells Source Type: research
In this study, we reviewed major human studies on the health risks of radiation exposure and showed that sex-related factors may potentially influence the long-term response to radiation exposure. Available data suggest that long-term radiosensitivity in women is higher than that in men who receive a comparable dose of radiation. The report on the biological effects of ionizing radiation (BEIR VII) published in 2006 by the National Academy of Sciences, United States emphasized that women may be at significantly greater risk of suffering and dying from radiation-induced cancer than men exposed to the same dose of radiation....
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | CT Scan | Docetaxel | Genetics | Health | Hormones | Men | PET Scan | Prostate Cancer | Science | Study | Taxotere | Universities